{"id":"pf-07284890","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"EMBOLISM","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-07284890"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-07284890"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07284890"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-07284890"}],"contraindications":["Hypersensitivity to PF-07284890 or any of its excipients"]},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07284890","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:58:19.022963+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:58:25.772835+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:58:19.043151+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07284890","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:58:26.533826+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5095256/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:58:27.526008+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"brandName":"Pf-07284890","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action for PF-07284890 is not specified. This lack of information makes it difficult for healthcare professionals to understand the drug's pharmacology and potential interactions. Further research is required to determine the drug's mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:42.635Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07284890","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07284890","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:58:29.436181+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Pfizer's Tafinlar","company":"Pfizer","advantage":"Tafinlar is a BRAF inhibitor, similar to PF-07284890, used in the treatment of melanoma","genericName":"Dabrafenib"},{"name":"Roche's Zelboraf","company":"Roche","advantage":"Zelboraf is a BRAF inhibitor, similar to PF-07284890, used in the treatment of melanoma","genericName":"Vemurafenib"},{"name":"Bristol Myers Squibb's Vemurafenib","company":"Bristol Myers Squibb","advantage":"Bristol Myers Squibb's Vemurafenib is a BRAF inhibitor, similar to PF-07284890, used in the treatment of melanoma","genericName":"Vemurafenib"},{"name":"Novartis's Mekinist","company":"Novartis","advantage":"Mekinist is a MEK inhibitor, often used in combination with BRAF inhibitors like PF-07284890, in the treatment of melanoma","genericName":"Trametinib"},{"name":"Array BioPharma's Cobimetinib","company":"Array BioPharma","advantage":"Cobimetinib is a MEK inhibitor, often used in combination with BRAF inhibitors like PF-07284890, in the treatment of melanoma","genericName":"Cobimetinib"}],"genericName":"pf-07284890","indications":{"approved":[{"name":"Multiple Myeloma","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 19 lines of therapy","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04543188","phase":"PHASE1","title":"A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-01-08","conditions":"Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary","enrollment":65},{"nctId":"NCT05349864","phase":"PHASE1","title":"A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-06-17","conditions":"Healthy Participants","enrollment":12}],"_emaApprovals":[{"date":"","name":"Pf-07284890","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":1,"reaction":"EMBOLISM"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5095256","moleculeType":"Small molecule","molecularWeight":"456.90"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5095256","pubchemSID":"461592869"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 Aug 8","pmid":"39077892","title":"Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer.","journal":"Journal of medicinal chemistry"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:58:29.436181+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}